Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 16 for:    LENALIDOMIDE AND Leukemia AND Azacitidine

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02863458
Recruitment Status : Active, not recruiting
First Posted : August 11, 2016
Last Update Posted : April 10, 2019
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
The Cleveland Clinic

Brief Summary:
The study aims to comprehensively analyze data from a large and unselected older AML population in the US, both treated and untreated. These data will widen understanding of treatment decisions for the older Acute Myeloid Leukemia (AML) population. Through use of the SEER-Medicare Registry, the effectiveness and impact of HMA treatments as well as the effectiveness of lenalidomide will be studied.

Condition or disease
Acute Myeloid Leukemia Myelodysplastic Syndromes

Detailed Description:

This will be the first study to comprehensively analyze data from a large and unselected older AML population in the US, both treated and untreated. These data will widen understanding of treatment decisions for the older AML population and shed light on the impact of HMA in this vulnerable population. The findings from this study will help identify the role of HMA (with its salient features of better tolerability and lesser toxicity) as a new treatment paradigm for older AML patients and enable comparison of outcomes with HMA vs other "conventional" leukemia therapies (intensive chemotherapy, low dose cytarabine or best supportive care). Additionally, with updated SEER-Medicare file carrying Medicare claims through 2013, this study will help analyze several long term outcome measures extending up to eight years for MDS patients treated with lenalidomide. Finally, the effectiveness of HMA in the SEER-Medicare MDS population will be studied by using SEER-Medicare data. This registry includes information on Medicare MDS beneficiaries - a population age cohort that has the highest incidence rates for MDS and a large sample size with absolute MDS cases approaching 40000, making it the largest MDS registry in the world.

The overall sample will include cases of MDS and AML newly diagnosed between 2001 and 2011 with claims from 2000 to 2012. Investigators estimate this will include approximately 50,000 patients.Therefore, the Target Follow Up design looks at patient records over a span of 12 years. Consists of patients with myeloid malignancies diagnosed during 2001-2011 at the age of 66 years or older and alive in September 2004 (i.e. 3 months after FDA approval of azacitidine for MDS), with known month of diagnosis, and not identified from death certificates or autopsy only, who had continuous Medicare Part A and B coverage, and were not enrolled in a health maintenance organization during the period of interest. The overall sample will include cases of MDS and AML newly diagnosed between 2001 and 2011 with claims from 2000 to 2012.

Variables of interest to be collected will include: MDS subtypes, age at diagnosis, sex, race, comorbidities, median household income at the zip code level, treatments (including supportive care) from diagnosis to AML progression, transfusion status, NCI comorbidity index score, response to treatments (using International Working Group criteria), physician characteristics (speciality data),and hospital characteristics (bed size, teaching status, case volume).


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 50000 participants
Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 12 Years
Official Title: Effectiveness of DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the United States
Actual Study Start Date : September 1, 2018
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : September 30, 2020





Primary Outcome Measures :
  1. Number of Participants on hypomethylating agents (HMA) and the effectiveness of HMA in the SEER-Medicare MDS population [ Time Frame: Analaysis restricted to patients alive at least 3 months after HMA approval. Patients will be followed from date of their first MDS claim (index date) through death or study end, whichever occurred first. ]
    Study patterns & determinants of HMA use in SEER-Medicare MDS population: Use of "2+BCBM" to ID registered & unregistered MDS cases. Map out geographical distribution of HMA use based on MDS patients reclassified by SMMRS, which will yield the proportion of higher-risk (HR) & lower-risk (LR) patients receiving HMA. Survival times to be analyzed using Cox models with time varying covariates. Predictors to be selected for both types of responses using learning interactions via hierarchical group-lasso regularization & monotone spline transformations. Utilization of non-parametric random Forest & random Survival Forest methods to build regression models & assess goodness of fit & functional form of the model-based results. Conduction of propensity score analyses of treatment effects as an alternative method for treatment-assignment bias correction. Propensity scores to be calculated using a generalized boosting method as implemented in the R package twang. Computations will be done in R.

  2. Develop predictive models of HMA treatment outcomes using SEER-Medicare data [ Time Frame: Analaysis restricted to patients alive at least 3 months after HMA approval. Patients will be followed from date of their first MDS claim (index date) through death or study end, whichever occurred first. ]
    To develop predictive models of HMA treatment outcomes using SEER-Medicare data: Treatment response analysis will include variables that are extractable from SEER-Medicare files that can be used to infer standard clinical response criteria. The outcome measures will include: 1) the proportion of patients completing an HMA therapeutic-length treatment episode (TTE) [6 cycles = ~6 months]; 2) changes in transfusion dependence; 3) the number of acute hospitalizations during the HMA therapy period; 4) the time from treatment initiation for MDS to progression to AML; and 5) overall survival from the time of HMA initiation.


Secondary Outcome Measures :
  1. Effectiveness of lenalidomide in the SEER-Medicare MDS population [ Time Frame: Analaysis restricted to patients alive at least 3 months after HMA approval. Patients will be followed from date of their first MDS claim (index date) through death or study end, whichever occurred first. ]
    An adequate sample size is used to undertake assessment of several variables that affect use of lenalidomide as well as treatment outcomes which aim to analyze (a) prescribing patters of lenalidomide among the low risk (LR)and high risk (HR) MDS with time (from 2006 to 2013) and consistency with clinical guidelines (b) trends in combination therapy (lenalidomide + other MDS therapies) with time (c) determinants of response to lenalidomide - underlying comorbidities, duration of treatment exposure (in terms of number of cycles), concomitant use of azacitidine or other MDS therapies with transfusion status (e) associations between lenalidomide and a variety of outcomes, including survival, progression to AML, secondary solid tumor malignancies and thromboembolic events and (e) differences in lenalidomide use and outcome between MDS Centers of Excellence (using data from MDS Clinical Consortium) versus community setting.

  2. Identify the role of HMA (with its salient features of better tolerability and lesser toxicity) as a new treatment paradigm for older AML patients and enable comparison of outcomes with HMA vs other "conventional" leukemia therapies. [ Time Frame: Analaysis restricted to patients alive at least 3 months after HMA approval. Patients will be followed from date of their first MDS claim (index date) through death or study end, whichever occurred first. ]
    To develop predictive models of HMA treatment outcomes using SEER-Medicare data: Treatment response analysis will include variables that are extractable from SEER-Medicare files that can be used to infer standard clinical response criteria. The outcome measures will include: 1) the proportion of patients completing an HMA therapeutic-length treatment episode (TTE) [6 cycles = ~6 months]; 2) changes in transfusion dependence; 3) the number of acute hospitalizations during the HMA therapy period; 4) the time from treatment initiation for MDS to progression to AML; and 5) overall survival from the time of HMA initiation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   66 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The overall sample will include cases of MDS and AML newly diagnosed between 2001 and 2011 with claims from 2000 to 2012. Investigators estimate this will include approximately 50,000 patients. To allow adequate time for HMA usage to begin to stabilize, our analysis will be restricted to patients alive at least 3 months after its approval. Decitabine received FDA approval for all subtypes of MDS in June 2006, but it was not covered by Medicare initially, so our analysis of it will be restricted to patients who were alive in January 2007. Patients will be followed from the date of their first MDS claim (index date) through death or study end, whichever occurred first.
Criteria

Inclusion Criteria:

  • patients with myeloid malignancies diagnosed during 2001-2011 at the age of 66 years or older
  • alive in September 2004 (i.e. 3 months after FDA approval of azacitidine for MDS)
  • known month of diagnosis, and not identified from death certificates or autopsy only
  • continuous Medicare Part A and B coverage, and were not enrolled in a health maintenance organization during the period of interest

Exclusion Criteria:

  • Anyone under 66 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02863458


Locations
Layout table for location information
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Celgene
Investigators
Layout table for investigator information
Principal Investigator: Sudipto Mukherjee, MD, MPh The Cleveland Clinic

Additional Information:

Layout table for additonal information
Responsible Party: The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT02863458     History of Changes
Other Study ID Numbers: 15-1066
First Posted: August 11, 2016    Key Record Dates
Last Update Posted: April 10, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: share study data with Celgene and will plan to publish a manuscript upon completion of the study
Keywords provided by The Cleveland Clinic:
MDS
AML
hypomethylating agents (HMA)
Surveillance Epidemiology and End Results (SEER)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lenalidomide
Myelodysplastic Syndromes
Bone Marrow Diseases
Hematologic Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents